

Validation of the MOG-AR Score

A Retrospective Multicenter Study

Sara Carta,^{1,*} Riccardo Tiberi,^{2,*} Nicola De Rossi,³ Giorgia Teresa Maniscalco,⁴ Giacomo Greco,⁵ Antonio Lotti,⁶ Alessandro Marziali,^{7,8} Arianna Sartori,⁹ Anna Favero,⁹ Francesca Rossi,¹⁰ Alessandro Dinoto,¹ Milena Trentinaglia,¹ Vanessa Chiodega,¹ Federica Boso,¹¹ Silvia Miente,¹² Stefano de Biase,¹² Francesca Caleri,¹³ Riccardo Orlandi,¹ Enis Guso,¹⁴ Irene Volonghi,¹⁴ Margherita Nosadini,¹⁵ Stefano Sartori,¹⁵ Pasqualina Palmieri,¹⁶ Alberto Cossu,¹⁶ Francesca Calabria,¹⁷ Pietro Zara,¹⁸ Maria Pia Giannoccaro,¹⁹ Luigi Zuliani,²⁰ Marika Vianello,²¹ Giovanna De Luca,²² Marco Zoccarato,²³ Anna de Mauro,²⁴ Luca Massacesi,⁶ Rosa Cortese,²⁴ Alberto Gajofatto,¹ Patrizia Rossi,²⁵ Elia Sechi,¹⁸ Alberto Vogrig,^{7,8} Valentina Damato,⁶ Matteo Gastaldi,⁵ and Sara Mariotto¹

Correspondence

Dr. Mariotto
sara.mariotto@gmail.com

Neurol Neuroimmunol Neuroinflamm 2026;13:e200547. doi:10.1212/NXI.000000000200547

Abstract

Objectives

A score evaluating age at onset, sex, clinical phenotype, and treatment received (MOG-AR) has been proposed to identify MOGAD patients at high relapse risk. The aim of this study was to validate the MOG-AR score in a multicenter cohort and to assess other variables potentially associated with relapses.

Methods

MOGAD patients were retrospectively enrolled from 24 centers. The MOG-AR score was applied and 4 categories of relapse risk were identified (grade I: lowest risk; grade IV: highest risk), accordingly. The association of MOG-AR score and additional variables with a relapsing course were then explored.

Results

Of 190 included patients, the median age at onset was 37 [IQR 23–51] years and 107 (56%) were female. A total of 78 patients (41%) experienced a relapse during a median of 43.6 months [24.8–75.4]. Using the proposed cutoff of 9, the MOG-AR score had a sensitivity of 53.9% [95% CI 55.6–73.9] and a specificity of 65.18% [95% CI 55.60–73.93]; area under the curve: 0.64 (95% CI 0.57–0.72). Among additional investigated factors, only immunosuppressive treatment after the presenting MOGAD attack was associated with a lower relapse risk.

Discussion

MOG-AR score failed to accurately predict a relapsing disease course. Only immunosuppressive treatment after the first event was significantly associated with a lower relapse risk.

*These authors contributed equally to the study as first authors.

¹Neurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Italy; ²Neurological Clinic, Experimental and Clinical Medicine Department, Marche Polytechnic University, Ancona, Italy; ³Multiple Sclerosis Center, ASST Spedali Civili di Brescia - P.O. Montichiari, Montichiari, Italy; ⁴Neurological Clinic and Stroke Unit and Multiple Sclerosis Center "A. Cardarelli" Hospital, Napoli, Italy; ⁵IRCCS Mondino Foundation, Pavia, Italy; ⁶Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), University of Florence, Italy; ⁷Department of Medicine (DMED), University of Udine, Italy; ⁸Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy; ⁹Department of Medicine, Surgery and Health Sciences, Neurology Unit, Cattinara University Hospital ASUGI, University of Trieste, Italy; ¹⁰Neurology Unit, Mater Salutis Hospital, Legnago, Verona, Italy; ¹¹Neurology Unit, Trento Hospital, Azienda Provinciale per i Servizi Sanitari (APSS) di Trento, Italy; ¹²Neurology Unit, Ospedale Dell'Angelo AULSS 3 Serenissima, Venice Mestre, Italy; ¹³Department of Neurology, MS Center, F. Tappeiner Hospital, Merano, Italy; ¹⁴Department of Continuity of Care and Frailty, Neurology Unit, ASST-Spedali Civili, Brescia, Italy; ¹⁵Paediatric Neurology and Neurophysiology Unit, Department of Women's and Children's Health, University Hospital of Padova. Neuroimmunology Group, Paediatric Research Institute "Città della Speranza", Padova, Italy; ¹⁶Child Neuropsychiatry Unit, Department of Children and Maternal Health, AOUI Verona, Full Member of European Reference Network EpiCARE, Italy; ¹⁷Neurology Unit, AOUI Verona, Italy; ¹⁸Neurology Unit, Department of Medicine, Surgery and Pharmacy, University Hospital of Sassari, Italy; ¹⁹IRCCS Istituto delle Scienze Neurologiche di Bologna, Italy; ²⁰Neurology Unit, AULSS8 Berica, Vicenza, Italy; ²¹UOC Neurologia, Azienda ULSS 2 Marca Trevigiana, Treviso, Italy; ²²Neurology Unit, Multiple Sclerosis Centre, SS Annunziata University Hospital, Chieti, Italy; ²³Neurology Unit O.S.A., Azienda Ospedale-Università di Padova, Italy; ²⁴Department of Medicine, Surgery and Neuroscience, University of Siena, Italy; and ²⁵Neurology Unit, AULSS7 Pedemontana, St Bassiano Hospital, Bassano del Grappa, Vicenza, Italy.

The Article Processing Charge was funded by Dept. of Neurosciences, University of Verona.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

e200547(1)

MORE ONLINE

Supplementary Material

Introduction

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an antibody-mediated disorder characterized by a demyelinating event and serum/CSF MOG antibodies (MOG-Abs) positivity.¹ Relapses can occur in 40%–60% of cases,² increasing to 70% over a follow-up > 5 years.^{3,4} Of note, disease course is highly unpredictable. Among factors potentially predicting relapses, MOG-Abs persistency, age, sex, ethnicity, onset phenotype, early relapses, early treatment with immunosuppression, and prolonged steroid have been identified.^{4–10}

Recently, a simple score (the MOG-AR Score), including onset age, sex, onset attack phenotype, use of immunosuppressive therapy, and duration of oral glucocorticoids treatment, has been proposed to identify patients at high relapse risk since onset.¹¹

The aim of this study was to provide the first validation of the MOG-AR Score in a national multicenter cohort and to assess other factors associated with a relapsing disease.

Methods

We retrospectively (January 2017–January 2025) identified patients with MOGAD¹ and at least 1-year follow-up recruited from 24 Italian centers.

Parameters of the MOG-AR Score (onset age ≥ 45 years, sex, attack phenotype, oral steroids use for at least 3 months, use of immunosuppressive treatment after the first event) were analyzed to assess association with disease course. Patients were stratified in 4 groups based on the MOG-AR score (grade 1: 0–4, grade 2: 5–8, grade 3: 9–12, grade 4: 13–16). Additional clinical and paraclinical data were collected and analyzed (eMethods).

Group comparisons were assessed using nonparametric tests (χ^2 and Mann–Whitney *U* tests). ROC curves were constructed to assess MOG-AR score performance.

True positive (TP), true negative (TN), false positive (FP), and false negative (FN) cases were identified considering that MOG-AR score ≥ 9 was reported as predictive of relapses.¹¹ Sensitivity, specificity, PPV, NPV, and accuracy with 95% CI were calculated.

Univariate binary logistic regression models, multivariate binary regression model, and Kaplan–Meier survival curves were performed to assess the risk of relapses (eMethods).

Standard Protocol Approvals, Registrations, and Patient Consents

The study was part of the research protocol approved by the Ethics Committees of the enrolling centers (eMethods).

Data Availability

Anonymized data not published within this article will be made available on request from any qualified investigator.

Results

Cohort Description

Among 260 patients, 34 were excluded for insufficient clinical information and 36 for insufficient follow-up. Of the 190 included patients, the median age at onset was 37 years [IQR 22.5–50.6], and 107 (56.4%) were female. The most frequent clinical presentation at onset were optic neuritis ($n = 91$, 47.9%), myelitis ($n = 48$, 25.3%), and acute disseminated encephalomyelitis ($n = 24$, 12.6%), Table 1. The median expanded disability status scale at onset was 3 [IQR 2–4.5]. High-dose steroids followed by at least 3 months oral steroid tapering were administered in 58 (30.7%) patients, while immunosuppressive treatment at first event was initiated in 54 (28.4%) patients. Of note, 18 (9.5%) patients received at least 3 months of steroid tapering and an immunosuppressive treatment after the first event. The median follow-up was 43.6 months [24.8–75.4], and 78 (41%) experienced at least 1 relapse, with an annualized relapse rate of 0.61 (SD 0.410).

MOG-AR Score Application

Overall, 23 (12.1%) patients were classified as grade 1, 51 (26.8%) as grade 2, 88 (46.3%) as grade 3, and 28 (14.7%) as grade 4. Relapses were observed in 17.4% ($n = 4$) of grade 1 cases, 33.3% ($n = 18$) of grade 2, 46.6% ($n = 41$) of grade 3, and 53.6% ($n = 15$) of grade 4, $p = 0.030$. ROC curve analysis using the MOG-AR showed an area under the curve of 0.644 (95% CI 0.565–0.723), eFigure 1.

Using the proposed cutoff of 9,¹¹ that was similar to the optimal cut-off identified in our cohort (Youden index = 9.5), MOG-AR score had a sensitivity of 53.85% (95% CI 55.60–73.93), a specificity of 65.18 (95% CI 55.60–73.93%), a PPV of 51.85% (95% CI 43.73–59.88), and a NPV of 88.97% (95% CI 60.63–72.76) with an accuracy of 60.53% (95% CI 53.19–67.53).

When assessing time to relapse with the Kaplan–Meier analysis ($n = 168$) according to the MOG-AR score, the difference was not statistically significant across different groups ($p = 0.120$), Figure 1.

Analysis of Individual Factors Associated With Relapse Risk


Oral steroids administration ≥ 3 months (0.51 95% CI 0.26–0.97, $p = 0.044$), receiving an additional acute treatment (OR 0.31 95% CI 0.12–0.80, $p = 0.016$), and starting immunosuppressive treatment after the first event (OR 0.37 95% CI 0.17–0.73, $p = 0.006$) were associated with lower relapse risk at univariate analysis (eTable 1). At multivariate analysis, only the initiation of immunosuppressive treatment after the first event was an independent factor associated with

Table 1 Cohort Description According to the Disease Course (Monophasic vs Relapsing)

| | Total cohort (n = 190) | Monophasic (n = 112) | Relapsing (n = 78) | p Value |
|--|------------------------|----------------------|--------------------|---------|
| Age at onset, median [IQR] | 37 [22.5–50.6] | 35.5 [19.8–49.6] | 39.5 [29.9–51.8] | 0.070 |
| Age<45 year-old at onset, n (%) | 69 (36.6) | 37 (33) | 32 (41) | 0.260 |
| Pediatric patients, n (%) | 30 (15.8) | 22 (19.5) | 8 (10.4) | 0.092 |
| Female n, (%) | 107 (56.4) | 63 (56.3) | 44 (56.4) | 0.983 |
| Infectious/vaccinal trigger, n, (%) | 50/145 (34.5) | 35/86 (40.2) | 15/59 (25.9) | 0.075 |
| Autoimmune comorbidities, n, (%) | 35 (18.4) | 20 (17.9) | 15 (19.2) | 0.756 |
| Clinical phenotype at onset, n (%) | | | | |
| Optic neuritis | 91 (47.9) | 50 (44.2) | 41 (53.2) | 0.223 |
| Myelitis | 48 (25.3) | 34 (30.4) | 14 (17.9) | 0.059 |
| ADEM | 24 (12.6) | 17 (15.2) | 7 (9) | 0.205 |
| Cortical encephalitis | 6 (3.2) | 3 (2.7) | 3 (3.8) | 0.651 |
| Brainstem syndrome | 10 (5.3) | 4 (3.6) | 6 (7.7) | 0.365 |
| Polyfocal onset | 8 (4.2) | 5 (4.5) | 3 (3.8) | 0.835 |
| Other | 3 (1.6) | 0 | 3 (3.8) | 0.036 |
| EDSS at onset (nadir) | 3 [2–4.5] | 3.5 [2–5.5] | 3 [2–4] | 0.160 |
| Visual acuity at onset (in patients with optic neuritis n = 91) | 0.35 [0.1–0.6] | 0.35 [0.1–0.7] | 0.35 [0.1–0.5] | 0.452 |
| Acute treatment strategies | | | | |
| MP iv | 175 (93.6) | 105 (94.6) | 70 (92.1) | 0.495 |
| Ivlg | 24 (12.6) | 18 (16.1) | 6 (7.7) | 0.087 |
| PLEX | 12 (6.3) | 11 (9.8) | 1 (1.3) | 0.017 |
| Steroid tapering ≥3 months | 58 (30.7) | 40 (35.7) | 18 (23.4) | 0.071 |
| Additional acute treatment (PLEX and/or Ivlg) | 30 (15.8) | 24 (21.4) | 6 (7.7) | 0.011 |
| Immunosuppressive treatment after the first event | 54 (28.4) | 41 (36.6) | 13 (16.7) | 0.004 |
| Azathioprine | 15 (27.8) | 10 (24.4) | 5 (38.46) | |
| MMF | 4 (7.4) | 4 (9.8) | 0 | |
| IvIG | 9 (16.7) | 8 (19.5) | 1 (7.7) | |
| Rituximab | 24 (44.4) | 18 (43.9) | 6 (46.2) | |
| Tocilizumab | 2 (3.7) | 1 (2.4) | 1 (7.7) | |
| CSF analysis | n = 168 | n = 97 | n = 71 | |
| Cell count (n/uL), median [IQR] | 5.5 [1–26.5] | 6 [1–37] | 2 [1–12.5] | 0.079 |
| Protein levels (n/uL), median [IQR] | 41.7 [28.8–57] | 44 [31–59] | 38.5 [23.8–54] | 0.138 |
| OCBs, n (%) | 68 (40.5) | 39 (40.2) | 29 (40.8) | 0.497 |
| Median follow-up, mo [IQR] | 43.6 [24.8–75.4] | 34.4 [21.6–57.2] | 61.1 [40.7–96.3] | <0.001 |
| EDSS at the last follow-up | 1 [0–2] | 1 [0–1] | 1.5 [1–2.5] | <0.001 |
| Visual acuity at last follow-up (in patients with optic neuritis n = 91) | 1 [0.9–1] | 1 [1–1] | 0.9 [0.8–1] | 0.040 |

Abbreviations: ADEM = acute disseminated encephalomyelitis; EDSS = expanded disability status scale; IQR = interquartile range; Ivlg = IV immunoglobulin; MMF = mycophenolate mofetil; MP IV = IV methylprednisolone; OCBs = oligoclonal bands; PLEX = plasma exchange.

Figure 1 Time to Reach the First Relapse According to the MOG-AR Score and Demographic Features



(A-D) Kaplan-Meier Analysis estimation of time to reach a first relapse according to MOG-AR score, sex, and age at onset ≥ 45 and pediatric onset.

a lower relapse risk (OR 0.42 95% CI 0.20–0.85, $p = 0.019$). When assessing time to relapse with Kaplan-Meier, female sex, age ≥ 45 , clinical phenotype, receiving an additional acute treatment, and use of corticosteroids ≥ 3 months were not associated with the risk of having a relapse, Figure 1. Similarly, pediatric onset, MOG-Abs status (seropositive at high titer, seropositive at low titer, unknown titer, CSF only positive), an infectious or vaccinal trigger, the use of a second line treatment in the acute stage, and oligoclonal bands presence were not correlated with relapse risk (Figures 1 and 2). Only starting an immunosuppressive treatment after the first event was associated with a lower relapse risk ($p = 0.035$).

Discussion

We herein observed that (1) the MOG-AR score cannot predict a relapsing course; (2) relapse risk is not influenced by age at onset, sex or clinical phenotype; and (3) prolonged


steroid taper, use of additional acute treatment, and initiation of immunotherapy after the first event are associated with a lower relapse risk at univariate analysis. However, at multivariate and survival analyses, only initiation of immunotherapy after the first event remained significantly associated with a reduced relapse risk.

Other previous studies have emphasized that MOGAD is a complex and heterogeneous disease with no reliable predictors of disease course.³

In our cohort, older age at onset was not associated with relapse risk. Previous studies reported contradictory results.⁷

Although some studies have reported a lower relapse risk in male patients,^{11,12} sex was not associated with disease course in our cohort. This finding is consistent with other prospective and retrospective studies.^{4,7}

Figure 2 Time to Reach the First Relapse According to Clinical Phenotype and Treatment Strategies



(A–D) Kaplan-Meier Analysis estimation of time to reach a first relapse according to clinical syndrome at onset, prolonged steroid taper, administration of an additional acute treatment, and use of an immunosuppressant after the first event.

Similarly to what already reported, patients presenting with myelitis had a trend toward a lower relapse rate.^{7,13} However, in our cohort, the clinical phenotype at disease presentation did not have a significant impact on relapse risk.

Of note, our data show that treatment is the main factor affecting relapse risk in MOGAD.^{7,13} Although a prolonged steroid course and the use of additional acute treatment decreased relapse risk at univariate analysis, this was not confirmed at survival/multivariate analyses. This may be related to the limited sample size. Conversely, the prompt initiation of immunosuppressive therapy was associated with a reduced relapse risk. However, the potential adverse effects of these treatments make controversial the initiation of immunosuppression after the first event. This is particularly relevant given that previous studies suggest that most of the long-term disability could be attributable to the initial attack.² Previous studies have shown the heterogeneity of

treatment strategies and the relevance of establishing consensus on how to treat MOGAD patients after the first event.¹⁴

The primary limitations of this study are its retrospective design, which may introduce selection and information biases, and the relatively small sample sizes in certain subgroup analyses, which limit the statistical power and generalizability of our findings and could partially explain the limited predictive values of the explore items.

Nevertheless, our findings confirm that MOGAD is a highly heterogeneous disease and that further research is needed to detect reliable markers able to predict a relapsing disease course. Our data underline how immunosuppressive treatment administered after the onset event can influence disease course, which administration should take into consideration the risk of overtreatment and adverse events occurrence.

Author Contributions

S. Carta: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. R. Tiberi: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. N. De Rossi: major role in the acquisition of data. G.T. Maniscalco: major role in the acquisition of data. G. Greco: major role in the acquisition of data. A. Lotti: major role in the acquisition of data. A. Marziali: major role in the acquisition of data. A. Sartori: major role in the acquisition of data. A. Favero: major role in the acquisition of data. F. Rossi: major role in the acquisition of data. A. Dinoto: major role in the acquisition of data. M. Trentinaglia: major role in the acquisition of data. V. Chiodega: major role in the acquisition of data. F. Bosco: major role in the acquisition of data. S. Miante: major role in the acquisition of data. S. de Biase: major role in the acquisition of data. F. Caleri: major role in the acquisition of data. R. Orlandi: major role in the acquisition of data. E. Guso: major role in the acquisition of data. I. Volonghi: major role in the acquisition of data. M. Nosadini: major role in the acquisition of data. S. Sartori: major role in the acquisition of data. P. Palmieri: major role in the acquisition of data. A. Cossu: major role in the acquisition of data. F. Calabria: major role in the acquisition of data. P. Zara: major role in the acquisition of data. M.P. Giannoccaro: major role in the acquisition of data. L. Zuliani: major role in the acquisition of data. M. Vianello: major role in the acquisition of data. G. De Luca: major role in the acquisition of data. M. Zoccarato: major role in the acquisition of data. A. de Mauro: major role in the acquisition of data. L. Massacesi: major role in the acquisition of data. R. Cortese: major role in the acquisition of data. A. Gajofatto: major role in the acquisition of data. P. Rossi: major role in the acquisition of data. E. Sechi: major role in the acquisition of data. A. Vogrig: major role in the acquisition of data. V. Damato: major role in the acquisition of data. M. Gastaldi: major role in the acquisition of data. S. Mariotto: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data.

Study Funding

The authors report no targeted funding.

Disclosure

A. Favero received Funding travel from Fidia; A. Sartori received funding for travel and/or speaker honoraria from

Biogen, Novartis, Roche; she is also Principal Investigator in clinical trials of Novartis and Roche; M. Zoccarato has received speaking honoraria from Roche and Pfizer; A. Gajofatto received honoraria for speaking and advisory boards from Amgen, Biogen, Merck, Novartis, Roche and Sanofi; S. Mariotto received speaker honoraria from Horizon, UCB, Novartis, Biogen, Sanofi, Alexion, Roche, the Sumaira Foundation, and Dynamics. Go to [Neurology.org/NN](https://www.neurology.org/NN) for full disclosures.

Publication History

Received by *Neurology*[®] *Neuroimmunology & Neuroinflammation* October 3, 2025. Accepted in final form December 11, 2025. Submitted and externally peer reviewed. The handling editor was Deputy Editor Anne-Katrin Pröbstel, MD.

References

- Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD panel proposed criteria. *Lancet Neurol*. 2023;22(3):268-282. doi:10.1016/S1474-4422(22)00431-8
- Cobo-calvo A, Ruiz A, Maillart E, et al.; OFSEP and NOMADMUS Study Group. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults the MOGADOR study. *Neurology*. 2018;90(21):e1858-e1869. doi:10.1212/WNL.0000000000005560
- Trewin BP, Brilot F, Reddel SW, Dale RC, Ramanathan S. MOGAD: a comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. *Autoimmun Rev*. 2025;24(1):103693. doi:10.1016/j.autrev.2024.103693
- Trewin BP, Dale RC, Qiu J, et al. Oral corticosteroid dosage and taper duration at onset in myelin oligodendrocyte glycoprotein antibody-associated disease influences time to first relapse. *J Neurol Neurosurg Psychiatry*. 2024;95(11):1054-1063. doi:10.1136/jnnp-2024-333463
- López-Chiriboga AS, Majed M, Fryer J, et al. Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders. *JAMA Neurol*. 2018;75(11):1355-1363. doi:10.1001/jamaneurol.2018.1814
- Waters P, Fadda G, Woodhall M, et al. Serial anti-myelin oligodendrocyte glycoprotein antibody analyses and outcomes in children with demyelinating syndromes. *JAMA Neurol*. 2020;77(1):82-93. doi:10.1001/jamaneurol.2019.2940
- Satukijchai C, Mariano R, Messina S, et al. Factors associated with relapse and treatment of myelin oligodendrocyte glycoprotein antibody-associated disease in the United Kingdom. *JAMA Netw Open*. 2022;5(1):E2142780. doi:10.1001/jamanetworkopen.2021.42780
- Deschamps R, Guillaume J, Ciron J, et al. Early maintenance treatment initiation and relapse risk mitigation after a first event of MOGAD in adults the MOGADOR2 study. *Neurology*. 2024;103(3):e209624. doi:10.1212/WNL.0000000000209624
- Kwon YN, Kim B, Kim JS, et al. Myelin oligodendrocyte glycoprotein-immunoglobulin G in the CSF clinical implication of testing and association with disability. *Neurol Neuroimmunol Neuroinflamm*. 2022;9(1):e1095. doi:10.1212/NXI.0000000000001095
- Chen B, Gomez-Figueroa E, Redenbaugh V, et al. Do early relapses predict the risk of long-term relapsing disease in an adult and paediatric cohort with MOGAD?. *Ann Neurol*. 2023;94(3):508-517. doi:10.1002/ana.26731
- Xu Y, Meng H, Fan M, et al. A simple score (MOG-AR) to identify individuals at high risk of relapse after MOGAD attack. *Neurol Neuroimmunol Neuroinflamm*. 2024;11(6):e200309. doi:10.1212/NXI.0000000000200309
- Virupakshiah A, Schoeps VA, Race J, et al. Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated disease. *J Neurol Neurosurg Psychiatry*. 2025;96(1):68-75. doi:10.1136/jnnp-2024-333464
- Huda S, Whittam D, Jackson R, et al. Predictors of relapse in MOG antibody associated disease: a cohort study. *BMJ Open*. 2021;11:e055392. doi:10.1136/bmjopen-2021-055392
- Whittam DH, Karthikeyan V, Gibbons E, et al. Treatment of MOG antibody associated disorders: results of an international survey. *J Neurol*. 2020;267(12):3565-3577. doi:10.1007/s00415-020-10026-y